Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence

Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence

Radiofrequency ablation (RFA) is subject to “heat-sink” effects, particularly for treatment of tumors adjacent to major vessels. In this retrospective study, 104 patients with 137 tumors (40 HCC, 10 ICC and 54 metastatic liver tumors) close to (≤1 cm from) the hepatic venous confluence underwent ste...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:HPB (Oxford, England) England), 2022-07, Vol.24 (7), p.1044-1054
Hauptverfasser: Schullian, Peter, Johnston, Edward, Laimer, Gregor, Scharll, Yannick, Putzer, Daniel, Eberle, Gernot, Kolbitsch, Christian, Amann, Arno, Stättner, Stefan, Bale, Reto
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1054
container_issue 7
container_start_page 1044
container_title HPB (Oxford, England)
container_volume 24
creator Schullian, Peter
Johnston, Edward
Laimer, Gregor
Scharll, Yannick
Putzer, Daniel
Eberle, Gernot
Kolbitsch, Christian
Amann, Arno
Stättner, Stefan
Bale, Reto
description Radiofrequency ablation (RFA) is subject to “heat-sink” effects, particularly for treatment of tumors adjacent to major vessels. In this retrospective study, 104 patients with 137 tumors (40 HCC, 10 ICC and 54 metastatic liver tumors) close to (≤1 cm from) the hepatic venous confluence underwent stereotactic RFA (SRFA) between June 2003 and June 2018. Median tumor size was 3.7 cm (1.4–8.5) for HCC, 6.4 cm (0.5–11) for ICC and 3.8 cm (0.5–13) for metastases. Endpoints comprised safety, local tumor control, overall and disease-free survival. The overall major complication rate was 16.0% (20/125 ablations), where 8 (40%) were successfully treated by the interventional radiologist in the same anesthetic session and did not prolong hospital stay. 134/137 (97.8%) tumors were successfully ablated at initial SRFA. Local recurrence (LR) developed in 19/137 tumors (13.9%). The median and overall survival (OS) rates at 1-, 3-, and 5- years from the date of the first SRFA were 51.5 months, 73.5%, 67.0%, and 49.7% for HCC, 14.6 months, 60.0%, 32.0% and 32.0% for ICC and 38.1 months, 91.4%, 56.5% and 27.9% for metastatic disease, respectively. SRFA represents a viable alternative to hepatic resection for challenging tumors at the hepatic venous confluence.
doi_str_mv 10.1016/j.hpb.2021.11.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2608537130</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1365182X21017056</els_id><sourcerecordid>2608537130</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-9a0f7364b85f121d6ac39a4cae32a8e984fe1b91a157aac8b5d3ae9ca549d4e73</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EEqXwA9g8siT44nyKCVV8SZU6ABKbdXEuqqs0DrZbiX-PozIz3Q3vc3rvYewWRAoCyvtdup3aNBMZpACpAHHGFpBXVZIVVX4ed1kWCdTZ1yW78n4nYlBAs2Cb90CObEAdjOYOO2N7R98HGvUPx3bAYOzIbc_DYW-d5xh42BLf0oQzcKTRHjzXduyHmaFrdtHj4Onmby7Z5_PTx-o1WW9e3laP60TLSoakQdFXsszbuughg65ELRvMNZLMsKamznuCtgGEokLUdVt0EqnRWORNl1Mll-zudHdyNrb1Qe2N1zQMOFJspLJS1IWsQIoYhVNUO-u9o15NzuzR_SgQapandirKU7M8BaCivMg8nBiKPxwNOeW1mf_rjCMdVGfNP_Qvv6J5AA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2608537130</pqid></control><display><type>article</type><title>Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Schullian, Peter ; Johnston, Edward ; Laimer, Gregor ; Scharll, Yannick ; Putzer, Daniel ; Eberle, Gernot ; Kolbitsch, Christian ; Amann, Arno ; Stättner, Stefan ; Bale, Reto</creator><creatorcontrib>Schullian, Peter ; Johnston, Edward ; Laimer, Gregor ; Scharll, Yannick ; Putzer, Daniel ; Eberle, Gernot ; Kolbitsch, Christian ; Amann, Arno ; Stättner, Stefan ; Bale, Reto</creatorcontrib><description>Radiofrequency ablation (RFA) is subject to “heat-sink” effects, particularly for treatment of tumors adjacent to major vessels. In this retrospective study, 104 patients with 137 tumors (40 HCC, 10 ICC and 54 metastatic liver tumors) close to (≤1 cm from) the hepatic venous confluence underwent stereotactic RFA (SRFA) between June 2003 and June 2018. Median tumor size was 3.7 cm (1.4–8.5) for HCC, 6.4 cm (0.5–11) for ICC and 3.8 cm (0.5–13) for metastases. Endpoints comprised safety, local tumor control, overall and disease-free survival. The overall major complication rate was 16.0% (20/125 ablations), where 8 (40%) were successfully treated by the interventional radiologist in the same anesthetic session and did not prolong hospital stay. 134/137 (97.8%) tumors were successfully ablated at initial SRFA. Local recurrence (LR) developed in 19/137 tumors (13.9%). The median and overall survival (OS) rates at 1-, 3-, and 5- years from the date of the first SRFA were 51.5 months, 73.5%, 67.0%, and 49.7% for HCC, 14.6 months, 60.0%, 32.0% and 32.0% for ICC and 38.1 months, 91.4%, 56.5% and 27.9% for metastatic disease, respectively. SRFA represents a viable alternative to hepatic resection for challenging tumors at the hepatic venous confluence.</description><identifier>ISSN: 1365-182X</identifier><identifier>EISSN: 1477-2574</identifier><identifier>DOI: 10.1016/j.hpb.2021.11.010</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>HPB (Oxford, England), 2022-07, Vol.24 (7), p.1044-1054</ispartof><rights>2021 International Hepato-Pancreato-Biliary Association Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-9a0f7364b85f121d6ac39a4cae32a8e984fe1b91a157aac8b5d3ae9ca549d4e73</citedby><cites>FETCH-LOGICAL-c373t-9a0f7364b85f121d6ac39a4cae32a8e984fe1b91a157aac8b5d3ae9ca549d4e73</cites><orcidid>0000-0003-0021-5792 ; 0000-0002-6116-4901 ; 0000-0002-1864-8900 ; 0000-0002-5226-7597 ; 0000-0002-8504-2968</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids></links><search><creatorcontrib>Schullian, Peter</creatorcontrib><creatorcontrib>Johnston, Edward</creatorcontrib><creatorcontrib>Laimer, Gregor</creatorcontrib><creatorcontrib>Scharll, Yannick</creatorcontrib><creatorcontrib>Putzer, Daniel</creatorcontrib><creatorcontrib>Eberle, Gernot</creatorcontrib><creatorcontrib>Kolbitsch, Christian</creatorcontrib><creatorcontrib>Amann, Arno</creatorcontrib><creatorcontrib>Stättner, Stefan</creatorcontrib><creatorcontrib>Bale, Reto</creatorcontrib><title>Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence</title><title>HPB (Oxford, England)</title><description>Radiofrequency ablation (RFA) is subject to “heat-sink” effects, particularly for treatment of tumors adjacent to major vessels. In this retrospective study, 104 patients with 137 tumors (40 HCC, 10 ICC and 54 metastatic liver tumors) close to (≤1 cm from) the hepatic venous confluence underwent stereotactic RFA (SRFA) between June 2003 and June 2018. Median tumor size was 3.7 cm (1.4–8.5) for HCC, 6.4 cm (0.5–11) for ICC and 3.8 cm (0.5–13) for metastases. Endpoints comprised safety, local tumor control, overall and disease-free survival. The overall major complication rate was 16.0% (20/125 ablations), where 8 (40%) were successfully treated by the interventional radiologist in the same anesthetic session and did not prolong hospital stay. 134/137 (97.8%) tumors were successfully ablated at initial SRFA. Local recurrence (LR) developed in 19/137 tumors (13.9%). The median and overall survival (OS) rates at 1-, 3-, and 5- years from the date of the first SRFA were 51.5 months, 73.5%, 67.0%, and 49.7% for HCC, 14.6 months, 60.0%, 32.0% and 32.0% for ICC and 38.1 months, 91.4%, 56.5% and 27.9% for metastatic disease, respectively. SRFA represents a viable alternative to hepatic resection for challenging tumors at the hepatic venous confluence.</description><issn>1365-182X</issn><issn>1477-2574</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAQhi0EEqXwA9g8siT44nyKCVV8SZU6ABKbdXEuqqs0DrZbiX-PozIz3Q3vc3rvYewWRAoCyvtdup3aNBMZpACpAHHGFpBXVZIVVX4ed1kWCdTZ1yW78n4nYlBAs2Cb90CObEAdjOYOO2N7R98HGvUPx3bAYOzIbc_DYW-d5xh42BLf0oQzcKTRHjzXduyHmaFrdtHj4Onmby7Z5_PTx-o1WW9e3laP60TLSoakQdFXsszbuughg65ELRvMNZLMsKamznuCtgGEokLUdVt0EqnRWORNl1Mll-zudHdyNrb1Qe2N1zQMOFJspLJS1IWsQIoYhVNUO-u9o15NzuzR_SgQapandirKU7M8BaCivMg8nBiKPxwNOeW1mf_rjCMdVGfNP_Qvv6J5AA</recordid><startdate>202207</startdate><enddate>202207</enddate><creator>Schullian, Peter</creator><creator>Johnston, Edward</creator><creator>Laimer, Gregor</creator><creator>Scharll, Yannick</creator><creator>Putzer, Daniel</creator><creator>Eberle, Gernot</creator><creator>Kolbitsch, Christian</creator><creator>Amann, Arno</creator><creator>Stättner, Stefan</creator><creator>Bale, Reto</creator><general>Elsevier Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0021-5792</orcidid><orcidid>https://orcid.org/0000-0002-6116-4901</orcidid><orcidid>https://orcid.org/0000-0002-1864-8900</orcidid><orcidid>https://orcid.org/0000-0002-5226-7597</orcidid><orcidid>https://orcid.org/0000-0002-8504-2968</orcidid></search><sort><creationdate>202207</creationdate><title>Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence</title><author>Schullian, Peter ; Johnston, Edward ; Laimer, Gregor ; Scharll, Yannick ; Putzer, Daniel ; Eberle, Gernot ; Kolbitsch, Christian ; Amann, Arno ; Stättner, Stefan ; Bale, Reto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-9a0f7364b85f121d6ac39a4cae32a8e984fe1b91a157aac8b5d3ae9ca549d4e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schullian, Peter</creatorcontrib><creatorcontrib>Johnston, Edward</creatorcontrib><creatorcontrib>Laimer, Gregor</creatorcontrib><creatorcontrib>Scharll, Yannick</creatorcontrib><creatorcontrib>Putzer, Daniel</creatorcontrib><creatorcontrib>Eberle, Gernot</creatorcontrib><creatorcontrib>Kolbitsch, Christian</creatorcontrib><creatorcontrib>Amann, Arno</creatorcontrib><creatorcontrib>Stättner, Stefan</creatorcontrib><creatorcontrib>Bale, Reto</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>HPB (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schullian, Peter</au><au>Johnston, Edward</au><au>Laimer, Gregor</au><au>Scharll, Yannick</au><au>Putzer, Daniel</au><au>Eberle, Gernot</au><au>Kolbitsch, Christian</au><au>Amann, Arno</au><au>Stättner, Stefan</au><au>Bale, Reto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence</atitle><jtitle>HPB (Oxford, England)</jtitle><date>2022-07</date><risdate>2022</risdate><volume>24</volume><issue>7</issue><spage>1044</spage><epage>1054</epage><pages>1044-1054</pages><issn>1365-182X</issn><eissn>1477-2574</eissn><abstract>Radiofrequency ablation (RFA) is subject to “heat-sink” effects, particularly for treatment of tumors adjacent to major vessels. In this retrospective study, 104 patients with 137 tumors (40 HCC, 10 ICC and 54 metastatic liver tumors) close to (≤1 cm from) the hepatic venous confluence underwent stereotactic RFA (SRFA) between June 2003 and June 2018. Median tumor size was 3.7 cm (1.4–8.5) for HCC, 6.4 cm (0.5–11) for ICC and 3.8 cm (0.5–13) for metastases. Endpoints comprised safety, local tumor control, overall and disease-free survival. The overall major complication rate was 16.0% (20/125 ablations), where 8 (40%) were successfully treated by the interventional radiologist in the same anesthetic session and did not prolong hospital stay. 134/137 (97.8%) tumors were successfully ablated at initial SRFA. Local recurrence (LR) developed in 19/137 tumors (13.9%). The median and overall survival (OS) rates at 1-, 3-, and 5- years from the date of the first SRFA were 51.5 months, 73.5%, 67.0%, and 49.7% for HCC, 14.6 months, 60.0%, 32.0% and 32.0% for ICC and 38.1 months, 91.4%, 56.5% and 27.9% for metastatic disease, respectively. SRFA represents a viable alternative to hepatic resection for challenging tumors at the hepatic venous confluence.</abstract><pub>Elsevier Ltd</pub><doi>10.1016/j.hpb.2021.11.010</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-0021-5792</orcidid><orcidid>https://orcid.org/0000-0002-6116-4901</orcidid><orcidid>https://orcid.org/0000-0002-1864-8900</orcidid><orcidid>https://orcid.org/0000-0002-5226-7597</orcidid><orcidid>https://orcid.org/0000-0002-8504-2968</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1365-182X
ispartof HPB (Oxford, England), 2022-07, Vol.24 (7), p.1044-1054
issn 1365-182X
1477-2574
language eng
recordid cdi_proquest_miscellaneous_2608537130
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
title Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T10%3A32%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stereotactic%20radiofrequency%20ablation%20of%20tumors%20at%20the%20hepatic%20venous%20confluence&rft.jtitle=HPB%20(Oxford,%20England)&rft.au=Schullian,%20Peter&rft.date=2022-07&rft.volume=24&rft.issue=7&rft.spage=1044&rft.epage=1054&rft.pages=1044-1054&rft.issn=1365-182X&rft.eissn=1477-2574&rft_id=info:doi/10.1016/j.hpb.2021.11.010&rft_dat=%3Cproquest_cross%3E2608537130%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2608537130&rft_id=info:pmid/&rft_els_id=S1365182X21017056&rfr_iscdi=true